We
prepared the condensed consolidated financial statements following the
requirements of the Securities and Exchange Commission (SEC) for interim
reporting. As permitted under those rules, certain footnotes or other financial
information that are normally required by accounting principles generally
accepted in the United States of America (U.S. GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month and nine-month periods ended
August 23, 2009, and August 24, 2008. Subsequent events have been evaluated
through November 4, 2009.
On
October 15, 2009, we completed our acquisition of Wyeth in a cash-and-stock
transaction valued, based on the closing market price of Pfizer s common stock
on that date, at $50.40 per share of Wyeth common stock, or a total of
approximately $68 billion. We have taken certain actions and incurred certain
costs associated with the transaction prior to the acquisition closing date that
are reflected in our financial statements. However, the assets acquired and
liabilities assumed from Wyeth, the consideration paid to acquire Wyeth, as well
as the results of Wyeth s operations, are not reflected in our Condensed
Consolidated Financial Statements as of and for the three and nine month periods
ended September 27, 2009. See Note 14. Subsequent Event
Acquisition of Wyeth for additional information.
We made
certain reclassifications to prior-period amounts to conform to the
third-quarter and nine-month 2009 presentations related to the presentation of
noncontrolling interests as a result of adopting a new accounting standard (see
Note 2. Adoption of New
Accounting Policies).
Revenues,
expenses, assets and liabilities can vary during each quarter of the year.
Therefore, the results and trends in these interim financial statements may not
be representative of those for the full year.
We are
responsible for the unaudited financial statements included in this
document. The financial statements include all normal and recurring
adjustments that are considered necessary for the fair presentation of our
financial position and operating results.
The
information included in this Quarterly Report on Form 10-Q should be read in
conjunction with the consolidated financial statements and accompanying notes
included in Pfizer s Annual Report on Form 10-K for the year ended December
31, 2008.
Note 2. Adoption of New
Accounting Policies
The
Financial Accounting Standards Board (FASB) has issued FASB Statement
No. 168, The FASB Accounting Standards Codification and the Hierarchy of
Generally Accepted Accounting Principles (Statement 168). Statement 168
establishes the FASB Accounting Standards Codification (Codification) as a
source of authoritative U.S. GAAP recognized by the FASB to be applied by
nongovernmental entities. As a result, these changes will have a significant
impact on how companies reference U.S. GAAP in their financial statements and in
their accounting policies for financial statements issued for interim and annual
periods ending after September 15, 2009. We have begun the
process of implementing the Codification in this quarterly report by providing
references to the Codification topics, as appropriate.
As of
July 1, 2009, we adopted the provisions of FASB Accounting Standards Update
(ASU) No. 2009-5 that provides additional guidance on measuring the fair value
of liabilities in the absence of observable market information, transfer
restrictions and non-performance risk assessment. The adoption of
these provisions did not have a significant impact on our consolidated financial
statements.
As of
March 30, 2009, we adopted the provisions of a new accounting standard issued by
the FASB that amends the guidance for evaluating and measuring
other-than-temporary impairments for available-for-sale or held-to-maturity
debt securities. The adoption of these provisions did not have a significant
impact on our consolidated financial statements.
As of
March 30, 2009, we adopted the provisions of a new accounting standard issued by
the FASB that provide additional guidance for estimating fair value in inactive
markets and the identification of disorderly transactions. We adopted these
provisions prospectively and they did not have a significant impact on our
consolidated financial statements, but could impact the accounting for
acquisitions after adoption, including our acquisition of Wyeth, and other
events, balances and transactions measured at fair value.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
As of
January 1, 2009, we adopted several new accounting standards issued by the FASB.
The adoption of these new standards did not have a significant impact on our
consolidated financial statements. In summary, these
provisions:
retain
the purchase method of accounting for acquisitions, but require a number
of changes, including changes in the way assets and liabilities are
recognized in purchase accounting. They also change the recognition of
assets acquired and liabilities assumed arising from contingencies,
require the capitalization of in-process research and development costs at
fair value and require the expensing of acquisition-related costs as
incurred. The adoption of these provisions will impact the accounting for
acquisitions after adoption, including our acquisition of
Wyeth.
amend
the factors considered in developing renewal or extension assumptions used
to determine the useful life of a recognized intangible asset. Among other
things, in the absence of historical experience, an entity will be
required to consider assumptions used by market participants. The adoption
of these provisions could impact the accounting for acquisitions after
adoption, including our acquisition of
Wyeth.
expand
the use of fair value, and related disclosure requirements and specify a
hierarchy of valuation techniques used to develop the fair value measures.
The adoption of these provisions will impact the accounting for
acquisitions after adoption, including our acquisition of Wyeth, and other
events, balances and transactions measured at fair
value.
provide
guidance for the accounting, reporting and disclosure of noncontrolling
interests, previously referred to as minority interests. A noncontrolling
interest represents the portion of equity (net assets) in a subsidiary not
attributable, directly or indirectly, to a parent. The adoption of these
provisions resulted in a number of changes to the presentation of our
consolidated financial statements, but the amounts associated with
noncontrolling interests are not significant. The adoption of these
provisions could impact our accounting for acquisitions after adoption
where we do not acquire 100% of the entity, and our accounting for the
deconsolidations of subsidiaries.
provide
guidance on determining whether an arrangement constitutes a collaborative
arrangement within the scope of the provisions; how costs incurred and
revenues generated on sales to third parties should be reported in the
income statement; how an entity should characterize payments on the income
statement; and what participants should disclose in the notes to the
financial statements about a collaborative arrangement. Accordingly,
additional disclosures are provided in Note 4. Collaborative
Arrangements.
provide
guidance that maintenance deposits paid by a lessee and subsequently
refunded only if a lessee fulfills a maintenance obligation will be
accounted for as a deposit asset.
clarify
how to account for certain transactions involving equity method
investments in areas such as: how to determine the initial carrying value
of the investment; how to allocate the difference between the investor s
carrying value and the investor s share of the underlying equity of the
investment; how to perform an impairment assessment of underlying
intangibles held by the investee; how to account for the investee s
issuance of additional shares; and how to account for an investment on the
cost method when it had been previously accounted for under the equity
method. The adoption of these provisions could impact the accounting for
equity method investments after
adoption.
clarify
the accounting for certain separately identifiable assets, which an
acquirer does not intend to actively use but intends to hold to prevent
its competitors from obtaining access to them. These provisions require an
acquirer to account for a defensive intangible asset as a separate unit of
accounting, which should be amortized to expense over the period the asset
diminishes in value. The adoption of these provisions could impact the
accounting for acquisitions after adoption, including our acquisition of
Wyeth.
Note 3.
Acquisitions
In the
second quarter of 2008, we acquired Encysive Pharmaceuticals Inc. (Encysive), a
biopharmaceutical company whose main asset is Thelin, which is used for the
treatment of pulmonary arterial hypertension. The cost of acquiring Encysive,
through a tender offer and subsequent merger, was approximately
$200 million, including transaction costs. Upon our acquisition of
Encysive, Encysive's change of control repurchase obligations under its
outstanding $130 million 2.5% convertible notes were triggered and, as a result,
Encysive repurchased the convertible notes in consideration for their par value
plus accrued interest in June 2008. In addition, in the second quarter of 2008,
we acquired Serenex, Inc. (Serenex), a privately held biotechnology company,
whose main asset is SNX-5422, an oral Heat Shock Protein 90 (Hsp90) for the
potential treatment of solid tumors and hematological malignancies and an
extensive Hsp90 inhibitor compound library, which has potential uses in treating
cancer, inflammatory and neurodegenerative diseases. In connection with these
acquisitions, through the third quarter of 2008, we recorded approximately $170
million in Acquisition-related
in-process research and development charges and approximately $450
million in intangible assets.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In the
first quarter of 2008, we acquired CovX, a privately held biotherapeutics
company specializing in preclinical oncology and metabolic research and the
developer of a biotherapeutics technology platform. Also in the first quarter of
2008, we acquired all the outstanding shares of Coley Pharmaceutical Group,
Inc., (Coley), a biopharmaceutical company specializing in vaccines and drug
candidates designed to fight certain cancers, allergy and asthma disorders, and
autoimmune diseases, for approximately $230 million. In connection with these
and two smaller acquisitions related to Animal Health, we recorded approximately
$398 million in Acquisition-related in-process
research and development charges during the first nine months of
2008. In the first nine
months of 2009, we resolved a contingency associated with CovX and recorded $20
million in Acquisition-related
in-process research and development charges. We did not consummate any
acquisitions in the first nine months of 2009.
Note 4. Collaborative
Arrangements
In the
normal course of business, we enter into collaborative arrangements with respect
to in-line medicines, as well as medicines in development, that require
completion of research and regulatory approval. Collaborative arrangements are
contractual agreements with third parties that involve a joint operating
activity, typically a research and/or commercialization effort, where both we
and our partner are active participants in the activity and are exposed to the
significant risks and rewards of the activity. Our rights and obligations under
our collaborative arrangements vary. For example, we have agreements to
co-promote pharmaceutical products discovered by other companies, and we have
agreements where we partner to co-develop and/or participate together in
commercializing, marketing, promoting, manufacturing, and/or distributing a drug
product.
Payments
to or from our collaboration partners are presented in the statement of income
based on the nature of the arrangement (including its contractual terms), the
nature of the payments and applicable accounting guidance. Under co-promotion
agreements, we record the amounts received from our partners as alliance
revenues, a component of Revenues, when our
co-promotion partners are the principal in the transaction and we receive a
share in their net sales or profits. Alliance revenues are recorded when our
co-promotion partners ship the product and title passes to their customers.
Expenses for selling and marketing these products are included in Selling, informational and